You are here:
Australia has one of the highest rates of methamphetamine dependence
in the world. While counselling is effective for many people with less
severe dependence, there is no proven medication treatment for severe
Lisdexamfetamine is a stimulant of the brain and is
approved in Australia for the treatment of Attention Deficit
Hyperactivity Disorder (ADHD). It is a once-daily oral medication
converted to dexamphetamine in the blood.
The aim of the LiMA
study is to test if lisdexamfetamine is effective in reducing
methamphetamine use, cravings and withdrawal symptoms. This will be a
randomised double-blind placebo-controlled study which means that one
group will receive lisdexamfetamine and another will receive a placebo
(a medication with no active ingredients), in addition to counselling.
Participants, clinicians and researchers involved in the study will not
know to which group they have been allocated. The two groups will be
compared and the findings will contribute to evidence for the future use
of lisdexamfetamine in the treatment of methamphetamine dependence.
information regarding the LiMA study please contact Teodora Zanesheva
on (02) 8382 4982 or email email@example.com
This research project has been approved by St Vincent’s Hospital, Sydney Human Research Ethics Committee; reference number HREC/16/SVH/222.